Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardinal HealthLTS:0HTG -0.37%81 Debt-to-EBITDA is 3.01 as of Mar. 2026, which is at its 10-year median of 3.01. GuruFocus rates LTS:0HTG with a GF Score™ of 81/100 and a GF Value™ of $141.66 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 90 Medical Distribution companies, Cardinal Health ranks worse than 53.33% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Cardinal Health's Debt-to-EBITDA or its related term are showing as below:
LTS:0HTG'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.59 Med: 3.01 Max: 96.64
Current: 2.73
During the past 13 years, the highest Debt-to-EBITDA Ratio of Cardinal Health was 96.64. The lowest was -2.59. And the median was 3.01.
LTS:0HTG's Debt-to-EBITDA is ranked worse than 53.33% of 90
companies
in the Medical Distribution industry
Industry Median: 2.45
vs LTS:0HTG: 2.73
Cardinal Health (LTS:0HTG) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Cardinal Health Debt-to-EBITDA Related Terms
Cardinal Health Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Cardinal Health's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0HTG vs COR, MCK, HSIC: Debt-to-EBITDA Comparison
For the Medical Distribution subindustry, Cardinal Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardinal Health Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cardinal Health's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cardinal Health's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Cardinal Health (LTS:0HTG) has a Debt-to-EBITDA of 3.01 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Cardinal Health. This is near median its historical median of 3.01. According to the industry distribution chart, Cardinal Health ranks #48 out of 90 companies in the Medical Distribution industry, placing it in the top 53.3%.
Is Cardinal Health's Debt-to-EBITDA too high?
Cardinal Health's current Debt-to-EBITDA of 3.01 is near median its 10-year median of 3.01. The Medical Distribution industry median Debt-to-EBITDA is 2.45. Cardinal Health's value of 3.01 is 22.9% above this industry median. Based on the distribution chart, Cardinal Health ranks #48 out of 90 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Cardinal Health has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cardinal Health's Debt-to-EBITDA compare to COR and MCK?
According to the Medical Distribution industry distribution chart, Cardinal Health ranks #48 out of 90 companies for Debt-to-EBITDA. This places Cardinal Health in the lower half of its industry. The industry median Debt-to-EBITDA is 2.45. Cardinal Health's value of 3.01 is 22.9% above this benchmark. While the company's 10-year median is 3.01 vs. the industry median of 2.45, Cardinal Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.45, based on 90 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardinal Health's current Debt-to-EBITDA of 3.01 is 22.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Cardinal Health. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardinal Health's current Debt-to-EBITDA is 3.01, which is near median its own 10-year median of 3.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardinal Health stock overvalued right now?
Based on GuruFocus' analysis, Cardinal Health (LTS:0HTG) is currently considered Significantly Overvalued. The stock's GF Value™ is $141.66, compared to a current price of $226.06 — trading 59.6% above its estimated fair value. The current Debt-to-EBITDA is 3.01, which is near median its 10-year median of 3.01 and 22.9% above the Medical Distribution industry median of 2.45. Cardinal Health's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Cardinal Health (LTS:0HTG), the current Debt-to-EBITDA is 3.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cardinal Health (LTS:0HTG) Overvalued in 2026?
Based on GuruFocus' analysis, Cardinal Health stock appears to be overvalued.
The current stock price of $226.06 is trading 59.6% above its estimated GF Value™ of $141.66.
GuruFocus considers Cardinal Health to be Significantly Overvalued.
Key valuation signals for LTS:0HTG:
Debt-to-EBITDA: 3.01 (near median its 10-year median of 3.01)
GF Value™: $141.66 vs. price of $226.06 (59.6% above fair value)
Industry Position: 22.9% above the Medical Distribution median (#48 of 90)
No single metric tells the full story. See the LTS:0HTG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
81GF Score
Get the complete analysis for LTS:0HTG
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HTG has been successfully added to your 
